文献速递肝病

推动脂肪性肝病公共卫生应对的全球研究优先议程

A global research priority agenda to advance public health responses to fatty liver disease.
PubMed 文献 · J Hepatol · 2023-06-20

该研究通过德尔菲法(两轮,第一轮344人、第二轮288人)制定全球脂肪性肝病研究优先议程,涵盖6个领域共28项优先事项。第二轮同意比例均值从第一轮的78.3%升至81.1%,5项获完全同意,其余23项合并同意率超过90%。作者认为该议程可推动全球应对这一公共卫生威胁。

要点

  • 全球约38%成人及13%儿童青少年患脂肪性肝病,为历史上最普遍的肝病。
  • 通过两轮德尔菲法(344人、288人)形成6领域28项研究优先事项。
  • 第二轮同意比例均值81.1%,23项合并同意率超过90%,13项同意率低于80%。

核心结论

  • 采用该多学科共识研究优先议程可推动脂肪性肝病应对的变革,减轻个体和社会危害,并通过预防、识别、治疗和照护主动改变其自然史。
  • 该议程应促进全球卫生界加快应对这一广泛且快速增长的公共卫生威胁。

研究设计与样本

  • 由9位联合主席起草初始研究优先事项,经40位核心作者审阅并在为期三天的面对面会议上讨论。
  • 采用德尔菲法,两轮中大型专家组(第一轮n=344,第二轮n=288)通过Qualtrics XM审阅优先事项。
  • 专家使用四点李克特量表表示同意并提供书面反馈,核心组在两轮之间修订草案;第二轮专家还对6个领域内的优先事项进行排序。

主要发现

  • 共识构建的脂肪性肝病研究议程涵盖28项优先事项。
  • 同意比例均值从第一轮的78.3升至第二轮的81.1。
  • 5项优先事项获得完全同意与部分同意的合并一致;其余23项合并同意率超过90%。
  • 除一项外所有优先事项均达到绝对多数同意(同意超过66.7%),但13项同意率低于80%,更多依赖部分同意以达到超过90%的合并同意。

关键数值与推荐

  • 6个领域为:流行病学、照护模式、治疗与照护、教育与意识、患者与社区视角、领导力与公共卫生政策。
  • 全球约38%成人及13%儿童青少年患有脂肪性肝病。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: An estimated 38% of adults worldwide have non-alcoholic fatty liver disease (NAFLD). From individual impacts to widespread public health and economic consequences, the implications of this disease are profound. This study aimed to develop an aligned, prioritised fatty liver disease research agenda for the global health community. METHODS: Nine co-chairs drafted initial research priorities, subsequently reviewed by 40 core authors and debated during a three-day in-person meeting. Following a Delphi methodology, over two rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the priorities, via Qualtrics XM, indicating agreement using a four-point Likert-scale and providing written feedback. The core group revised the draft priorities between rounds. In R2, panellists also ranked the priorities within six domains: epidemiology, models of care, treatment and care, education and awareness, patient and community perspectives, and leadership and public health policy. RESULTS: The consensus-built fatty liver disease research agenda encompasses 28 priorities. The mean percentage of 'agree' responses increased from 78.3 in R1 to 81.1 in R2. Five priorities received unanimous combined agreement ('agree' + 'somewhat agree'); the remaining 23 priorities had >90% combined agreement. While all but one of the priorities exhibited at least a super-majority of agreement (>66.7% 'agree'), 13 priorities had <80% 'agree', with greater reliance on 'somewhat agree' to achieve >90% combined agreement. CONCLUSIONS: Adopting this multidisciplinary consensus-built research priorities agenda can deliver a step-change in addressing fatty liver disease, mitigating against its individual and societal harms and proactively altering its natural history through prevention, identification, treatment, and care. This agenda should catalyse the global health community's efforts to advance and accelerate responses to this widespread and fast-growing public health threat. IMPACT AND IMPLICATIONS: An estimated 38% of adults and 13% of children and adolescents worldwide have fatty liver disease, making it the most prevalent liver disease in history. Despite substantial scientific progress in the past three decades, the burden continues to grow, with an urgent need to advance understanding of how to prevent, manage, and treat the disease. Through a global consensus process, a multidisciplinary group agreed on 28 research priorities covering a broad range of themes, from disease burden, treatment, and health system responses to awareness and policy. The findings have relevance for clinical and non-clinical researchers as well as funders working on fatty liver disease and non-communicable diseases more broadly, setting out a prioritised, ranked research agenda for turning the tide on this fast-growing public health threat.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Lazarus JV, Mark HE, Allen AM, et al. A global research priority agenda to advance public health responses to fatty liver disease. J Hepatol. 2023. PMID: 37353401. doi:10.1016/j.jhep.2023.04.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。